GlycanAge has secured $4,200,000 in investment capital from investors. The company specializes in redefining the understanding and measurement of aging through its focus on glycans. These complex molecules, backed by over 30 years of research and more than 300 peer-reviewed publications, regulate inflammation and immune system function, offering a unique lens into biological age and how lifestyle, chronic inflammation, and environmental factors influence the aging process.
GlycanAge's flagship product, the GlycanAge® test, is a simple at-home solution designed to show how the body is actually aging, going beyond genetic predispositions. This test provides actionable insights, empowering users and healthcare providers to track the impact of interventions and optimize preventative care strategies. The company reports that its test is currently used by over 1,500 providers and tens of thousands of customers globally.
This funding round is significant for GlycanAge, enabling the company to accelerate its growth initiatives and expand its market presence. The capital will be strategically deployed to enhance the accessibility of its proprietary biological age test, further develop its research into glycan biomarkers, and scale its operations to meet increasing demand. The investment underscores the growing recognition of GlycanAge's innovative approach to personalized health and longevity.
Looking ahead, GlycanAge plans to solidify its position at the forefront of the longevity space. The company's strategy involves continued innovation in glycan research and making its insights accessible to a broader audience, fostering a proactive approach to health and empowering individuals to live healthier for longer through a deeper understanding of their biological age.
